TY - JOUR
T1 - Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome
AU - Yamagishi, Yuko
AU - Kuwahara, Motoi
AU - Suzuki, Hidekazu
AU - Sonoo, Masahiro
AU - Kuwabara, Satoshi
AU - Yokota, Takanori
AU - Nomura, Kyoichi
AU - Chiba, Atsuro
AU - Kaji, Ryuji
AU - Kanda, Takashi
AU - Kaida, Ken Ichi
AU - Mutoh, Tatsuro
AU - Yamasaki, Ryo
AU - Takashima, Hiroshi
AU - Matsui, Makoto
AU - Nishiyama, Kazutoshi
AU - Sobue, Gen
AU - Kusunoki, Susumu
N1 - Publisher Copyright:
©
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Objective Approximately 15%-20% of patients with Guillain-Barré syndrome (GBS) are unable to walk independently at 6 months from the onset of neurological symptom. The modified Erasmus GBS outcome score (mEGOS) has been reported as a prognostic tool. Herein we investigated the association between a poor outcome, inability to walk independently at 6 months and presence of antiganglioside antibodies. Methods The clinical and serological data of 177 patients with GBS were retrospectively collected in Japan to assess the associations between a poor outcome and serum IgG antibodies against each ganglioside (GM1, GD1a, GalNAc-GD1a, GQ1b and GT1a). In addition, we investigated whether the combination of mEGOS and serum IgG antibodies against gangliosides is useful in predicting a poor outcome. Results The patients with IgG anti-GD1a antibodies more frequently showed poor outcomes than those without these antibodies (9 (36%) of 25 vs 8 (6%) of 127 patients, p<0.001). Particularly, 80% showed a poor outcome when they had both serum IgG anti-GD1a antibody and a high mEGOS of ≥10 on day 7 of admission. Conclusions The combination of serum IgG anti-GD1a antibodies and a high mEGOS could help in making a more accurate prognosis of patients than mEGOS alone, especially for predicting poor outcomes.
AB - Objective Approximately 15%-20% of patients with Guillain-Barré syndrome (GBS) are unable to walk independently at 6 months from the onset of neurological symptom. The modified Erasmus GBS outcome score (mEGOS) has been reported as a prognostic tool. Herein we investigated the association between a poor outcome, inability to walk independently at 6 months and presence of antiganglioside antibodies. Methods The clinical and serological data of 177 patients with GBS were retrospectively collected in Japan to assess the associations between a poor outcome and serum IgG antibodies against each ganglioside (GM1, GD1a, GalNAc-GD1a, GQ1b and GT1a). In addition, we investigated whether the combination of mEGOS and serum IgG antibodies against gangliosides is useful in predicting a poor outcome. Results The patients with IgG anti-GD1a antibodies more frequently showed poor outcomes than those without these antibodies (9 (36%) of 25 vs 8 (6%) of 127 patients, p<0.001). Particularly, 80% showed a poor outcome when they had both serum IgG anti-GD1a antibody and a high mEGOS of ≥10 on day 7 of admission. Conclusions The combination of serum IgG anti-GD1a antibodies and a high mEGOS could help in making a more accurate prognosis of patients than mEGOS alone, especially for predicting poor outcomes.
KW - Guillain-Barre syndrome
KW - ganglioside
KW - neuropathy
UR - http://www.scopus.com/inward/record.url?scp=85094184308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094184308&partnerID=8YFLogxK
U2 - 10.1136/jnnp-2020-323960
DO - 10.1136/jnnp-2020-323960
M3 - Article
C2 - 33041261
AN - SCOPUS:85094184308
SN - 0022-3050
VL - 91
SP - 1339
EP - 1342
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
IS - 12
ER -